M&A Deal Summary |
|
|---|---|
| Date | 2014-02-28 |
| Target | OTC Products |
| Sector | Medical Products |
| Buyer(s) | Perrigo Company |
| Sellers(s) | Aspen Global |
| Deal Type | Divestiture |
| Deal Value | 51M USD |
SEARCH BY
Try For Free 7-Day Free Trial
| Category | Company |
|---|---|
| Founded | 1887 |
| Sector | Life Science |
| Employees | 9,140 |
| Revenue | 4.7B USD (2023) |
Perrigo Company is a global healthcare supplier that develops, manufactures and distributes over-the-counter (OTC) and prescription (Rx) pharmaceuticals, nutritional products, and active pharmaceutical ingredients (API), as well as receives royalties from Multiple Sclerosis drug Tysabri®. The company is the world's largest manufacturer of OTC pharmaceutical products for the store brand market and an industry leader in pharmaceutical technologies. Perrigo Company was founded in 1887 and is based in Dublin, Ireland.
| DEAL STATS | # |
|---|---|
| Overall | 21 of 31 |
| Sector (Medical Products) | 8 of 10 |
| Type (Divestiture) | 3 of 7 |
| Country (Mauritius) | 1 of 1 |
| Year (2014) | 1 of 2 |
| Size (of disclosed) | 14 of 23 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-12-18 |
Elan
Dublin, Ireland Elan is a biotechnology company, headquartered in Dublin, Ireland, committed to making a difference in the lives of patients and their families by dedicating itself to bringing innovations in science to fill significant unmet medical needs that continue to exist around the world. It focused on discovering and developing advanced therapies in neurodegenerative and autoimmune diseases. |
Buy | $8.6B |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2014-11-04 |
Omega Pharma NV
Nazareth, Belgium Omega Pharma NV is a healthcare company. Omega Pharma provides medicines, health and personal care that can be purchased at the pharmacy. |
Buy | €3.6B |
South African-based Aspen is a supplier of branded and generic pharmaceuticals in more than 150 countries across the world and of consumer and nutritional products in selected territories. Aspen has production capabilities for a wide variety of product types including tablets, capsules, eye drops, injectable products (including lyophilized vials), oral contraceptives, form-filled seals, suppositories, liquids, creams, ointments, infant nutritional products, and specialist active pharmaceutical ingredients.
| DEAL STATS | # |
|---|---|
| Overall | 1 of 2 |
| Sector (Medical Products) | 1 of 1 |
| Type (Divestiture) | 1 of 2 |
| Country (Mauritius) | 1 of 1 |
| Year (2014) | 1 of 1 |
| Size (of disclosed) | 2 of 2 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2013-09-30 |
GSK s Arixtra Fraxiparine brands
United Kingdom Arixtra and Fraxiparine/Fraxodi are made at a sterile site and the ability to manufacture steriles is globally recognised as a specialist activity resulting in limited possible competition. This is a factor further underlined by the increased complexity of the manufacturing process of Fraxiparine/Fraxodi due to the biological nature of the active pharmaceutical ingredients (“API”) used in their production. |
Buy | £700M |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2019-11-11 |
Aspen Global - Japanese Operations
Japan Aspen Global, Inc.'s Japanese Operations is a provider of branded and generic pharmaceuticals. |
Sell | R6.5B |
